Dianthus Therapeutics Investor Relations Material
Latest events
M&A Announcement
Dianthus Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Dianthus Therapeutics Inc
Access all reports
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Key slides for Dianthus Therapeutics Inc
Corporate Presentation
Dianthus Therapeutics Inc
Corporate Presentation
Dianthus Therapeutics Inc
Latest articles
Swoosh: The Nike Story
The Nike story and how the company rose to the top of its industry, as well as insights into the company philosophy and way of doing business.
17 May 2024
Burberry: From WWI Trench Coats to Global Luxury
Explore Burberry's journey from a small outfitter to a global luxury fashion icon under Daniel Lee's creative vision.
17 May 2024
Phil Knight: The Entrepreneurial Genius Behind Nike
The life, work, and legacy of Nike’s legendary founder Phil Knight and his path to the top of athletic footwear and apparel.
16 May 2024
Ticker symbol
Country
🇺🇸 United States